Delivery of an EBV episome by a self-circularizing helper-dependent adenovirus: Long-term transgene expression in immunocompetent mice

Gene Therapy

Volumn 17, Issue 10, 2010, Pages 1288-1293

  Gil, J S ^a   Gallaher, S D ^a   Berk, A J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

eukaryotic plasmid; stable transformation; transduction; viral vector

Indexed keywords

ADENOVIRUS VECTOR; CRE RECOMBINASE; HERPESVIRUS VECTOR; PLASMID DNA;

ARTICLE; B LYMPHOCYTE; DNA INTEGRATION; DNA VECTOR; EPISOME; EPSTEIN BARR VIRUS; GENE CONVERSION; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HYBRID GENE; HYBRIDIZATION; IMMUNOCOMPETENCE; LATENT VIRUS INFECTION; LIVER CELL; LIVER CELL NUCLEUS; MAMMAL CELL; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; TISSUE SPECIFICITY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; B-LYMPHOCYTES; CELLS, CULTURED; GENES, REPORTER; HELA CELLS; HEPATOCYTES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPETENCE; MICE; MICE, INBRED BALB C; MICE, NUDE; PLASMIDS; TRANSDUCTION, GENETIC; TRANSGENES;

ADENOVIRIDAE; EUKARYOTA; HUMAN HERPESVIRUS 4; MAMMALIA; MUS;

EID: 77958013792     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.75     Document Type: Article

References (25)

1. Tsurumi T, Fujita M, Kudoh A. Latent and lytic Epstein-Barr virus replication strategies. Rev Med Virol 2005; 15: 3-15.
2. Yates J, Warren N, Sugden B. Stable replication of plasmid derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
3. Krysan PJ, Calos MP. Epstein-Barr virus-based vectors that replicate in rodent cells. Gene 1993; 136: 137-143.
4. Lindner SE, Sugden B. The plasmid replicon of Epstein-Barr virus: mechanistic insights into efficient, licensed, extrachromo-somal replication in human cells. Plasmid 2007; 58: 1-12.
5. Nanbo A, Sugden A, Sugden B. The coupling of synthesis and partitioning of EBV's plasmid replicon is revealed in live cells. EMBO J 2007; 26: 4252-4262.
6. Wohlgemuth JG, Kang SH, Bulboaca GH, Nawotka KA, Calos MP. Long-term gene expression from autonomously replicating vectors in mammalian cells. Gene Therapy 1996; 3: 503-512.
7. Stoll SM, Sclimenti CR, Baba EJ, Meuse L, Kay MA, Calos MP. Epstein-Barr virus/human vector provides high-level, long-term expression of alpha1-antitrypsin in mice. Mol Ther 2001; 4: 122-129.
8. Segura MM, Alba R, Bosch A, Chillon M. Advances in helper-dependent adenoviral vector research. Curr Gene Ther 2008; 8: 222-235.
9. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565-13570.
10. Brunetti-Pierri N, Ng P. Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Therapy 2008; 15: 553-560.
11. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409.
12. Lowenstein PR. With a little help from my f(X)riends!: the basis of Ad5-mediated transduction of the liver revealed. Mol Ther 2008; 16: 1004-1006.
13. Okuyama T, Huber RM, Bowling W, Pearline R, Kennedy SC, Flye MW et al. Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha 1-antitrypsin promoter dramatically increases expression of human alpha 1-antitrypsin in vivo. Hum Gene Ther 1996; 7: 637-645.
14. Gallaher SD, Gil JS, Dorigo O, Berk AJ. Robust in vivo transduction of a genetically stable Epstein-Barr virus episome to hepatocytes in mice by a hybrid viral vector. J Virol 2009; 83: 3249-3257.
15. Tan BT, Wu L, Berk AJ. An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency. J Virol 1999; 73: 7582-7589.
16. Dorigo O, Gil JS, Gallaher SD, Tan BT, Castro MG, Lowenstein PR et al. Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J Virol 2004; 78: 6556-6566.
17. Al-Dosari M, Zhang G, Knapp JE, Liu D. Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver. Biochem Biophys Res Commun 2006; 339: 673-678.
18. Pastore L, Morral N, Zhou H, Garcia R, Parks RJ, Kochanek S et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999; 10: 1773-1781.
19. Martin GR, Evans MJ. Differentiation of clonal lines of teratocarcinoma cells: formation of embryoid bodies in vitro. Proc Natl Acad Sci USA 1975; 72: 1441-1445.
20. Umana P, Gerdes CA, Stone D, Davis JR, Ward D, Castro MG et al. Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol 2001; 19: 582-585.
21. Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001; 3: 28-35.
22. Barr D, Tubb J, Ferguson D, Scaria A, Lieber A, Wilson C et al. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Therapy 1995; 2: 151-155.
23. Brooks AR, Harkins RN, Wang P, Qian HS, Liu P, Rubanyi GM. Transcriptional silencing is associated with extensive methyla-tion of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 2004; 6: 395-404.
24. Loser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol 1998; 72: 180-190.
25. Lowenstein PR, Kroeger K, Castro MG. Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunolo-gical synapses. Neurotherapeutics 2007; 4: 715-724.